Ontario is picking up a third of the bill for a drug plant upgrade north of Toronto.

Piramal Pharma Solutions, the contract development and manufacturing organization (CDMO) arm of Piramal Pharma Ltd. (NSE: PPLPHARMA; BSE: 543635), said on September 29 that its drug substance site in Aurora, Ontario, has been awarded $1,753,620 from the province’s Life Sciences Scale-Up Fund (LSSUF). The money supports a $5,314,000 infrastructure upgrade at the plant. Piramal says the project will create 12 jobs and protect 183 existing ones.

The check is small. What makes it worth a look is where it’s going: a North American plant that makes active pharmaceutical ingredients (APIs), the part of a medicine that actually does the work, for other drug companies. And it lands just as Piramal’s contract business has started growing again.

The Math Behind the Grant

The release uses dollar signs but never names a currency. The LSSUF is an Ontario program with its caps set in Canadian dollars, so this article treats every figure from the release as C$.

Divide the grant by the project cost and you get 33.0%. That’s not a coincidence. According to Ontario’s program page, a successful applicant can receive up to C$2.5 million, covering no more than 33% of eligible project costs, and has to secure the other 67% itself. Piramal’s award sits right at that ceiling.

By our own calculation, not a figure the release gives, that leaves roughly C$3.56 million for Piramal to fund. This assumes the C$5.314 million is the full eligible project cost. The release is worded loosely enough that it isn’t certain.

A note on language. Both the company and the province call this an “investment.” It is not an equity stake. The LSSUF is a cost-share program, and companies apply through Transfer Payment Ontario, the province’s online system for grant funding.

What the Upgrade Covers, and What’s Missing

Specifics are thin. The release says the work will strengthen R&D and clinical-stage API production and help keep critical drug substances commercially available. Peter DeYoung, CEO of Piramal Global Pharma, adds that it includes sustainability, efficiency and site modernization projects.

That’s about it. There’s no equipment list. No start date or completion target. No word on whether the grant carries job-retention conditions or repayment terms. No customers, products or therapeutic areas are named.

The release also says the funding will help Piramal commercialize Ontario-made health technologies for new markets. It never says which ones. For a CDMO that makes ingredients for other companies’ drugs, that line is hard to pin down.

A Site With a Long Record

Aurora sits about 50 kilometers north of Toronto. According to Piramal’s facility page, the site opened in 1982 as Torcan and came to Piramal in 2005 when it bought Avecia Pharmaceuticals. It handles process development and API manufacturing from gram scale up to hundreds of kilograms, including highly potent compounds that need special containment.

Piramal says the site has supported 15 commercial API launches and has an inspection history with the U.S. FDA, Health Canada and Japan’s PMDA.

Bigger money has gone in before. In January 2020, Piramal broke ground on a new API manufacturing wing it valued at roughly C$25 million. Trade coverage later put total spending on the site at about C$30 million, with the expansion done in 2022. The two figures come from different sources and may count different things.

Next to that, this project reads as a refresh. Not a new build.

A Global Company in a Fund Built for SMEs

Here’s the wrinkle. Ontario pitches the LSSUF at small and medium-sized enterprises (SMEs). Piramal Pharma is neither small nor medium. The group reported revenue of ₹2,270 crore for the quarter ended June 30, 2026, with its CDMO segment alone at ₹1,187 crore.

The eligibility rules explain how it fits. The test is headcount in Ontario, between 5 and 500 full-time equivalent employees, not the size of the global parent. Aurora’s 183 existing roles sit comfortably inside that band. Applicants also have to file a corporate family tree, so the province knew who owns the site.

Nothing in the public record suggests the award breaks any rule. It does show that a unit of a multinational with 17 facilities can tap a pool aimed at scale-ups. The fund launched in 2024 with C$24 million, and the 2026 Ontario Budget added another C$24 million. This single grant works out to about 7% of one of those tranches, again by our own calculation.

What It Means for Piramal Pharma

The grant won’t move earnings. The timing is more interesting.

Piramal’s CDMO segment logged four straight quarters of year-over-year declines before returning to growth in Q1 FY27, when segment revenue rose 19%. Group EBITDA margin widened to 12.5% from 8.5% a year earlier. The company still booked a consolidated net loss of about ₹69 crore, narrower than the prior year’s ₹82 crore. Brokerage commentary after the quarter flagged slow conversion of customer inquiries into signed projects.

So a North American API site gets a modest upgrade, with public money covering a third, while the business it serves is still proving its recovery. The 12 new jobs and 183 protected positions are company projections, not confirmed outcomes. The release gives no date for when they should be in place.

Sources

• Piramal Pharma Solutions: Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma’s Aurora Facility, PRNewswire, September 29, 2026. Primary source release.
• Government of Ontario: Life Sciences Scale-Up Fund, cited for the C$2.5 million cap, the 33% cost-share ceiling, the SME headcount test, the corporate family tree requirement, and the grant application system, none of which appeared in the release.
• Piramal Pharma Solutions: Aurora, Canada Facility, cited for the site’s history, capabilities, commercial API launches, and regulatory inspection record.
• Piramal Pharma Solutions Invests ~CAD$25 Million to Expand its Aurora, Canada Facility, PRNewswire, January 28, 2020, cited for the prior API wing expansion.
• Pharmaceutical Technology: Piramal Pharma Solutions’ Manufacturing Facility Expansion, Aurora, Canada, cited for total site investment and the 2022 completion of the expansion.
• Piramal Pharma Limited Announces Results for Q1 FY27, PRNewswire, July 29, 2026, cited for group revenue, CDMO segment growth, EBITDA margin, net loss, and facility count.
• Whalesbook: Piramal Pharma Outlook Improves After Q1 FY27 Revenue Beat, cited for the CDMO segment’s prior four quarters of decline and brokerage commentary on order conversion.
• Dawn Gallagher Murphy, MPP: Ontario Supporting Over 1,000 Good-Paying Jobs in Life Science Sector, cited to corroborate the fund’s 2024 launch and the additional C$24 million in the 2026 Ontario Budget.

Editorial Disclosure

This article reports on a press release issued by Piramal Pharma Solutions on September 29, 2026 regarding Life Sciences Scale-Up Fund support from the Government of Ontario for its Aurora, Ontario drug substance facility. Securities and corporate structures discussed: Piramal Pharma Ltd. (National Stock Exchange of India: PPLPHARMA; BSE: 543635), the listed parent of Piramal Pharma Solutions and its Aurora operating entity. Program eligibility and cost-share terms, the site’s history and prior expansion, and Piramal Pharma’s Q1 FY27 financial results were drawn from independent sources cited above, since the original release did not address them. The roughly C$3.56 million company share and the 7% share of a single fund tranche are calculated inferences, not figures reported in the release. BioTech Stocks Daily was not compensated for this coverage and has not received, nor will it accept, any compensation, direct or indirect, from Piramal Pharma Ltd., Piramal Pharma Solutions, the Government of Ontario, or any other corporate or third-party sponsor for the preparation or publication of this coverage. No staff member, principal, or affiliate of BioTech Stocks Daily holds a position, option, or financial interest in any of the securities mentioned as of the date of publication. Statements regarding job creation and retention, project scope and completion, the commercial availability of drug substances, the commercialization of health technologies, and future business growth are forward-looking statements. They involve substantial risks, operational uncertainties, and market variables; actual project outcomes, timelines, employment figures, and financial results may differ materially. Investments in pharmaceutical manufacturing and contract development companies carry significant financial risk, including customer concentration, capacity utilization, regulatory inspection outcomes, and currency exposure, which can result in the loss of invested capital. This article is published strictly for independent news reporting, market context, and educational purposes only. It does not constitute an investment recommendation, endorsement, or professional financial, legal, or tax advice. Furthermore, this content is not medical advice; patients and healthcare providers should consult appropriate clinical professionals for medical guidance.

For full details regarding our editorial independence, publishing policies, and comprehensive risk disclaimers, please see our full DISCLAIMER.